

Company Announcement

30 May 2011

Novo Nordisk A/S – Share repurchase programme

On 28 April 2011 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 2.0 billion in the period from 28 April 2011 to 2 August 2011.

Since the announcement as of 23 May 2011, the following transactions have been made under the programme:

	Number of shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	857,000		550,235,947
23 May 2011	45,000	647.4800	29,136,600
24 May 2011	45,000	648.9720	29,203,740
25 May 2011	45,000	653.2600	29,396,700
26 May 2011	50,000	647.9800	32,399,000
27 May 2011	45,000	648.1800	29,168,100
Accumulated under the programme	1,087,000		699,540,087

Transactions related to Novo Nordisk's incentive programmes have resulted in a net sale by Novo Nordisk of 2,275 B shares in the period from 23 May 2011 to 27 May 2011. The shares in these transactions were not part of the Safe Harbour repurchase programme.

With the transactions stated above, Novo Nordisk owns a total of 11,312,814 treasury shares, corresponding to 2.0% of the share capital. The total amount of shares in the company is 580,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares worth DKK 10.0 billion during 2011. As of 27 May 2011, Novo Nordisk has repurchased a total of 4,140,338 B shares equal to a transaction value of DKK 2,699,539,888.

Novo Nordisk is a global healthcare company with 88 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 31,400 employees in 74 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.

Further information:

Media:

Outside North America:
Anne Margrethe Hauge
Tel: (+45) 4442 3450
amhg@novonordisk.com

In North America:
Ken Inchausti
Tel: (+1) 609 514 8316
kiau@novonordisk.com

Investors:

Klaus Bülow Davidsen
Tel: (+45) 4442 3176
klda@novonordisk.com

Jannick Lindegaard
Tel: (+45) 4442 4765
jlis@novonordisk.com

Frank Daniel Mersebach
Tel: (+45) 4442 0604
fdni@novonordisk.com